Typbar-TCV is a Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine. Typbar-TCV is the world's 1st clinically proven conjugate typhoid vaccine.
Typbar TCV is indicated as a preventative vaccine against Typhoid which is caused by Salmonella Typhi and Paratyphi.
The WHO recently recommended that routine childhood immunization programs include Typbar TCV as a single intramuscular dose for primary vaccination of infants and children from 6 months of age.
It is also recommended for adults ≤45 years of age and in catch-up campaigns in children ≤15 years of age in typhoid-endemic regions.
Clinical Trial NCT03600025: Cellular Immune Responses in Typhoid Fever Patients and Vaccinees
This Phase 1 clinical trial is to further understand the role of mucosal-associated invariant T cell (MAIT) and natural killer (NK) cell responses in typhoid fever or following vaccination. Transcriptome profiling of human immune responses to S. Typhi infection is not clearly understood. Establishing successful infection by S. Typhi evasion of T cell and neutrophil responses need to be investigated to better understand the correlates of protection.